Print Page  Close Window


SEC Filings

S-1/A
OREXIGEN THERAPEUTICS, INC. filed this Form S-1/A on 02/16/2007
Entire Document
 
Table of Contents

 
The following table summarizes, as of December 31, 2006, the differences between the number of shares of common stock purchased from us, after giving effect to the conversion of all of our outstanding shares of preferred stock into common stock, the total effective cash consideration paid, and the average price per share paid by our existing stockholders and by our new investors purchasing stock in this offering at an assumed initial public offering price of $      per share (the mid-point of the price range set forth on the cover page of this prospectus) before deducting the estimated underwriting discounts and commissions and estimated offering costs payable by us:
 
                                         
    Shares Purchased     Total Consideration     Average Price
 
    Number     Percent     Amount     Percent     per Share  
 
Existing stockholders before this offering
    37,720,558       %   $ 76,060,866       %   $ 2.02  
Investors participating in this offering
                                       
                                         
Total
            100.0 %   $         100.0 %        
                                         
 
Each $1.00 increase or decrease in the assumed public offering price of $      per share (the mid-point of the price range set forth on the cover page of this prospectus) would increase or decrease total consideration paid by new investors, total consideration paid by all stockholders and the average price per share paid by all stockholders by $      million, $      million and $     , respectively, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering costs payable by us.
 
If the underwriters exercise their overallotment option in full, our existing stockholders would own     % and our new investors would own     % of the total number of shares of our common stock outstanding after this offering.
 
The above information assumes no exercise of stock options outstanding as of December 31, 2006, and excludes:
 
  •      4,594,125 shares of common stock issuable upon the exercise of options outstanding as of December 31, 2006 at a weighted average exercise price of $0.62 per share; and
 
  •                shares of our common stock reserved for future issuance under our 2007 equity incentive award plan, which will become effective on the day prior to the day on which we become subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act (including 1,516,479 shares of common stock reserved for future grant or issuance under our 2004 stock plan, which shares will be added to the shares to be reserved under our 2007 equity incentive award plan upon the effectiveness of the 2007 equity incentive award plan).


44